Adverse drug reactions

Abstract

Get full access to this article

View all access options for this article.

References

Neilan

. Merck pulls Vioxx painkiller from market, and stock plunges. The New York Times. 2004 September 30. Available: www.nytimes.com/2004/09/30/business/30CND-MERCK.html (accessed December 21, 2013).

MedEffect™ Canada. Health Canada website. Available: www.healthcanada.gc.ca/medeffect (accessed August 7, 2012).

Bombardier

Laine

Reicin

. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.

Bresalier

Sandler

Quan

. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.

Lexchin

. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ 2005;172:765-7.

World Health Organization. Pharmacovigilance. Available: www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/index.html (accessed February 17, 2012).

McMorran

McEnaney

Adverse reaction and incident reporting—2012. Canadian Adverse Reaction Newsletter 2013;23:2-5. Available: www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/bulletin/carn-bcei_v23n3-eng.pdf (accessed August 8, 2013).

Naranjo

Busto

Sellers

. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.

The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. Available: http://www.who-umc.org/Graphics/26649.pdf (accessed August 7, 2012).

10.

Køber

Torp-Pedersen

McMurray

JJV

. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87.

11.

Connolly

Camm

Halperin

. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76.

12.

Rigotti

Pipe

Benowitz

. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010;121:221-9.

13.

Singh

Loke

Spangler

Furberg

CD.

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359-66.

14.

Prochaska

Hilton

JF.

Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012;344:e2856.

15.

Mills

Thorlund

Eapen

. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014;129:28-41.

16.

Institute for Safe Medication Practices. Signals for dabigatran and metoclopramide. QuarterWatch 2011; January 2012. Available: www.ismp.org/quarterwatch/pdfs/2011Q1.pdf (accessed August 7, 2012).

17.

Uchino

Hernandez

. Dabigatran association with higher risk of acute coronary events. Arch Intern Med 2012;172:397-402.

18.

Health Canada. Progressive licensing. Available: www.hc-sc.gc.ca/dhp-mps/homologation-licensing/index-eng.php (accessed December 21, 2013).